ResearcherZhejiang UniversityNo recent work listed
Youqing Shen
Matched on ORCID iD 0000-0003-1837-7976; OpenAlex author ID A5029767971. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 21
2017: 3 papers · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper
Papers 6
- Prodrug nanoparticles rationally integrating stroma modification and chemotherapy to treat metastatic pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2021.121176↗
- Excipient-free nanodispersion of 7-ethyl-10-hydroxycamptothecin exerts potent therapeutic effects against pancreatic cancer cell lines and patient-derived xeno… Co-author DOI 10.1016/j.canlet.2019.08.019↗
- New path to treating pancreatic cancer: TRAIL gene delivery targeting the fibroblast-enriched tumor microenvironment. Last author DOI 10.1016/j.jconrel.2018.07.047↗
- Targeted Co-delivery of PTX and TR3 siRNA by PTP Peptide Modified Dendrimer for the Treatment of Pancreatic Cancer. Co-author DOI 10.1002/smll.201602697↗
- Terminating the criminal collaboration in pancreatic cancer: Nanoparticle-based synergistic therapy for overcoming fibroblast-induced drug resistance. Last author DOI 10.1016/j.biomaterials.2017.08.002↗
- GDC-0449 improves the antitumor activity of nano-doxorubicin in pancreatic cancer in a fibroblast-enriched microenvironment. Last author DOI 10.1038/s41598-017-13869-0↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Quan Zhou · 4 shared papers, 2017–2021 · strength 0.36
- Paper Prodrug nanoparticles rationally integrating stroma modification and chemotherapy to treat metastatic pancreatic cancer. DOI 10.1016/j.biomaterials.2021.121176↗
- Paper GDC-0449 improves the antitumor activity of nano-doxorubicin in pancreatic cancer in a fibroblast-enriched microenviron… DOI 10.1038/s41598-017-13869-0↗
- Paper Excipient-free nanodispersion of 7-ethyl-10-hydroxycamptothecin exerts potent therapeutic effects against pancreatic ca… DOI 10.1016/j.canlet.2019.08.019↗
- Xiangrui Liu · 4 shared papers, 2017–2021 · strength 0.36
- Paper Prodrug nanoparticles rationally integrating stroma modification and chemotherapy to treat metastatic pancreatic cancer. DOI 10.1016/j.biomaterials.2021.121176↗
- Paper GDC-0449 improves the antitumor activity of nano-doxorubicin in pancreatic cancer in a fibroblast-enriched microenviron… DOI 10.1038/s41598-017-13869-0↗
- Paper New path to treating pancreatic cancer: TRAIL gene delivery targeting the fibroblast-enriched tumor microenvironment. DOI 10.1016/j.jconrel.2018.07.047↗
- Haiping Jiang · 2 shared papers, 2018–2021 · strength 0.20
- Paper Prodrug nanoparticles rationally integrating stroma modification and chemotherapy to treat metastatic pancreatic cancer. DOI 10.1016/j.biomaterials.2021.121176↗
- Paper New path to treating pancreatic cancer: TRAIL gene delivery targeting the fibroblast-enriched tumor microenvironment. DOI 10.1016/j.jconrel.2018.07.047↗
- Liying Wang · 2 shared papers, 2017–2021 · strength 0.18
- Paper Prodrug nanoparticles rationally integrating stroma modification and chemotherapy to treat metastatic pancreatic cancer. DOI 10.1016/j.biomaterials.2021.121176↗
- Paper Terminating the criminal collaboration in pancreatic cancer: Nanoparticle-based synergistic therapy for overcoming fibr… DOI 10.1016/j.biomaterials.2017.08.002↗
- Weilin Wang · 2 shared papers, 2017–2019 · strength 0.14
- Paper Excipient-free nanodispersion of 7-ethyl-10-hydroxycamptothecin exerts potent therapeutic effects against pancreatic ca… DOI 10.1016/j.canlet.2019.08.019↗
- Paper Terminating the criminal collaboration in pancreatic cancer: Nanoparticle-based synergistic therapy for overcoming fibr… DOI 10.1016/j.biomaterials.2017.08.002↗
- Xiangsheng Liu · 1 shared paper, 2021 · strength 0.12
- Liping Cao · 1 shared paper, 2021 · strength 0.12
- Huan Meng · 1 shared paper, 2021 · strength 0.12
- Hao Xu · 1 shared paper, 2019 · strength 0.08
- Linshi Zhang · 1 shared paper, 2019 · strength 0.08
- Rong Du · 1 shared paper, 2019 · strength 0.08
- Yuan Ding · 1 shared paper, 2019 · strength 0.08
- Jiarong Zhou · 1 shared paper, 2019 · strength 0.08
- Huilin Zheng · 1 shared paper, 2019 · strength 0.08
- Lisong Teng · 1 shared paper, 2018 · strength 0.08
- Qinglian Hu · 1 shared paper, 2017 · strength 0.07
- Qi Zheng Yao · 1 shared paper, 2017 · strength 0.07
- Yang Li · 1 shared paper, 2017 · strength 0.07
- Guping Tang · 1 shared paper, 2017 · strength 0.07
- Zipeng Lu · 1 shared paper, 2017 · strength 0.06
- Yi Miao · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.